The Criteria for the clinical use of immunoglobulin in Australia (the Criteria) undergoes periodic review to reflect the latest scientific evidence and expert advice from our National Immunoglobulin Governance Advisory Committee and its Specialist Working Groups.
This page summarises the changes to the Criteria which were implemented in November 2025. Changes are applied immediately to new authorisations and to existing authorisations at the next continuing treatment request, unless otherwise stated. For more information about any of these changes, please contact the Ig Governance team at IgGovernance@blood.gov.au.
Autoimmune encephalitis mediated by antibodies targeting cell-surface antigens (AMAE) – Version 3.4
- Minor typographical changes.
Cicatricial pemphigoid (CP) or mucous membrane pemphigoid (MMP) – Version 3.1
- Added information to the qualifying criteria recommending a trial of rituximab unless contraindicated.
- Other minor typographical changes.
Epidermolysis bullosa acquisita – Version 3.1
- Added information to the qualifying criteria recommending a trial of rituximab unless contraindicated.
- Other minor typographical changes.
Erythromelalgia – Version 3.0
- New not supported condition added.
Immune thrombocytopenic purpura (ITP) – adult – Version 3.3
- Provided clarity in clinician and assessment instructions for evidence item relating to maintenance platelet count.
- Life-threatening indication now appears first in the list.
- Other minor typographical changes.
Immune thrombocytopenic purpura (ITP) - in children 15 years and younger – Version 3.3
- Provided clarity in clinician and assessment instructions for one evidence item relating to maintenance platelet count.
- Other minor typographical changes.
Long COVID – Version 3.0
- New not supported condition added.
Pemphigus foliaceus (PF) – Version 3.1
- Amended qualifying and review criteria to require a trial of rituximab unless strongly contraindicated.
- Other minor typographical changes.
Pemphigus vulgaris (PV) – Version 3.1
- Amended qualifying and review criteria to require a trial of rituximab unless strongly contraindicated.
- Other minor typographical changes.
Recurrent miscarriage / recurrent fetal loss (with or without antiphospholipid syndrome) – Version 3.1
- Information about recurrent miscarriage added to the existing entry for recurrent fetal loss (with or without antiphospholipid syndrome).
Last updated: 03 Feb 2026